221 related articles for article (PubMed ID: 25237928)
21. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
22. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
23. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
24. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
Roy L; Samyesudhas SJ; Carrasco M; Li J; Joseph S; Dahl R; Cowden Dahl KD
Oncotarget; 2014 Sep; 5(18):8355-66. PubMed ID: 25327563
[TBL] [Abstract][Full Text] [Related]
25. Gene regulatory networking reveals the molecular cue to lysophosphatidic acid-induced metabolic adaptations in ovarian cancer cells.
Ray U; Roy Chowdhury S; Vasudevan M; Bankar K; Roychoudhury S; Roy SS
Mol Oncol; 2017 May; 11(5):491-516. PubMed ID: 28236660
[TBL] [Abstract][Full Text] [Related]
26. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
27. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
28. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
30. IKK inhibition increases bortezomib effectiveness in ovarian cancer.
Singha B; Gatla HR; Phyo S; Patel A; Chen ZS; Vancurova I
Oncotarget; 2015 Sep; 6(28):26347-58. PubMed ID: 26267322
[TBL] [Abstract][Full Text] [Related]
31. NF-κB Participates in the Stem Cell Phenotype of Ovarian Cancer Cells.
Gonzalez-Torres C; Gaytan-Cervantes J; Vazquez-Santillan K; Mandujano-Tinoco EA; Ceballos-Cancino G; Garcia-Venzor A; Zampedri C; Sanchez-Maldonado P; Mojica-Espinosa R; Jimenez-Hernandez LE; Maldonado V
Arch Med Res; 2017 May; 48(4):343-351. PubMed ID: 28886875
[TBL] [Abstract][Full Text] [Related]
32. Growth inhibition of ovarian tumor-initiating cells by niclosamide.
Yo YT; Lin YW; Wang YC; Balch C; Huang RL; Chan MW; Sytwu HK; Chen CK; Chang CC; Nephew KP; Huang T; Yu MH; Lai HC
Mol Cancer Ther; 2012 Aug; 11(8):1703-12. PubMed ID: 22576131
[TBL] [Abstract][Full Text] [Related]
33. Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells.
Wu S; Wang X; Chen J; Chen Y
Biochem Biophys Res Commun; 2013 May; 434(4):898-903. PubMed ID: 23624503
[TBL] [Abstract][Full Text] [Related]
34. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
Cheng W; Liu T; Wan X; Gao Y; Wang H
FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Gao Y; Foster R; Yang X; Feng Y; Shen JK; Mankin HJ; Hornicek FJ; Amiji MM; Duan Z
Oncotarget; 2015 Apr; 6(11):9313-26. PubMed ID: 25823654
[TBL] [Abstract][Full Text] [Related]
37. Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.
Park J; Shim JK; Kang JH; Choi J; Chang JH; Kim SY; Kang SG
Neuro Oncol; 2018 Jun; 20(7):954-965. PubMed ID: 29294080
[TBL] [Abstract][Full Text] [Related]
38. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
39. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
[TBL] [Abstract][Full Text] [Related]
40. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.
Wang YC; Yo YT; Lee HY; Liao YP; Chao TK; Su PH; Lai HC
Am J Pathol; 2012 Mar; 180(3):1159-1169. PubMed ID: 22222226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]